Federal Register / Vol 79, No. 236 / Tuesday, December 9, 2014 / Notices / Pages 73086-73087
Agenda: The committee will discuss the safety and efficacy of new drug application (NDA) 022517, proposed trade name NOCDURNA (established name: desmopressin), orally disintegrating sublingual tablets submitted by Ferring Pharmaceuticals, Inc. The proposed indication is treatment of nocturia due to nocturnal polyuria in adults who awaken two or more times each night to void.
Date and Time: The meeting will be held on January 12, 2015, from 8 a.m. to 5 p.m.Share